I
Ian Homer Y. Cua
Researcher at University of Sydney
Publications - 19
Citations - 1757
Ian Homer Y. Cua is an academic researcher from University of Sydney. The author has contributed to research in topics: Fatty liver & Medicine. The author has an hindex of 9, co-authored 15 publications receiving 1109 citations.
Papers
More filters
Journal ArticleDOI
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow,Mihir Gandhi,Say Beng Tan,Maung Win Khin,Ariunaa Khasbazar,Janus P. Ong,Su Pin Choo,Peng Chung Cheow,Chanisa Chotipanich,Kieron Lim,Laurentius A. Lesmana,Tjakra Manuaba,Boon Koon Yoong,Aloysius Raj,Chiong Soon Law,Ian Homer Y. Cua,Rolley Rey Lobo,Catherine Teh,Yun Hwan Kim,Yun Won Jong,Ho-Seong Han,Si Hyun Bae,Hyun-Ki Yoon,Rheun Chuan Lee,Chien Fu Hung,Cheng Yuan Peng,Po-Chin Liang,Adam Bartlett,Kenneth Y.Y. Kok,Choon Hua Thng,Albert S. C. Low,Anthony S. W. Goh,Kiang Hiong Tay,Richard Hoau Gong Lo,Brian K. P. Goh,David Chee Eng Ng,Ganesh Lekurwale,Wei Ming Liew,Val Gebski,Kenneth Seck Wai Mak,Khee Chee Soo +40 more
TL;DR: In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib, and the improved toxicity profile of RE may inform treatment choice in selected patients.
Journal ArticleDOI
The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam,Shiv Kumar Sarin,Vincent Wai-Sun Wong,Jian-Gao Fan,Takumi Kawaguchi,Sang Hoon Ahn,Ming-Hua Zheng,Gamal Shiha,Yusuf Yilmaz,Rino Alvani Gani,Shahinul Alam,Yock Young Dan,Jia-Horng Kao,Saeed Hamid,Ian Homer Y. Cua,Wah-Kheong Chan,Diana A. Payawal,Soek Siam Tan,Tawesak Tanwandee,Leon A. Adams,Manoj Kumar,Masao Omata,Jacob George +22 more
TL;DR: The clinical practice guidelines of the Asian Pacific Association for the Study of the Liver on MAFLD are presented to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data.
Journal ArticleDOI
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
Shiv Kumar Sarin,Ashok Choudhury,George K. K. Lau,Ming-Hua Zheng,Dong Ji,Sherief Abd-Elsalam,J.S. Hwang,Xiaolong Qi,Ian Homer Y. Cua,Jeong Ill Suh,Jun Gi Park,Opass Putcharoen,Apichat Kaewdech,Teerha Piratvisuth,Sombat Treeprasertsuk,Soo-Young Park,Salisa Wejnaruemarn,Diana A. Payawal,Oidov Baatarkhuu,Sang Hoon Ahn,Chang Dong Yeo,Uzziel Romar Alonzo,Tserendorj Chinbayar,Imelda Maria Loho,Osamu Yokosuka,Wasim Jafri,S. G. Tan,Lau Ing Soo,Tawesak Tanwandee,Rino Alvani Gani,Lovkesh Anand,Eslam Saber Esmail,Mai Khalaf,Shahinul Alam,Chun-Yu Lin,Wan-Long Chuang,Arvinder S. Soin,Hitendra K. Garg,Kemal Fariz Kalista,Badamnachin Batsukh,Hery Djagat Purnomo,Vijay Pal Dara,Pravin Rathi,Mamun Al Mahtab,Akash Shukla,Manoj K. Sharma,Masao Omata +46 more
TL;DR: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated, which makes the patients with diabetes and obesity more vulnerable and should be closely monitored.
Journal ArticleDOI
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3
Hossein Poustchi,Francesco Negro,Jason M. Hui,Ian Homer Y. Cua,Laura Rubbia Brandt,James G. Kench,Jacob George +6 more
TL;DR: Even in treatment-responsive genotypes 2 and 3, high HOMA-IR is associated with a reduced response, suggesting improving insulin sensitivity may be a useful adjunct to anti-viral therapy in patients with genotype 2 or 3 infection.
Journal ArticleDOI
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease : Role of insulin resistance and hepatic steatosis
Elisabetta Bugianesi,Gulio Marchesini,Elena Gentilcore,Ian Homer Y. Cua,Ester Vanni,Mario Rizzetto,Jacob George +6 more
TL;DR: In conclusion, insulin resistance is an independent predictor of advanced fibrosis in both NAFLD and CHC‐3, but the extent of steatosis contributes to advanced disease only inNAFLD.